AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06776471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin-based flowable filling material
Description: Preventive restoration
Study NCT06776900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Supine position
Description: An assistant will be asked to hold the tongue in protrusion using a gauze held by a Magill forceps (preventing it from falling backwards). The operator will introduce the bronchoscope orally allowing its advancement till it reaches the laryngeal inlet. The glottic view will be graded from 1 (larynx is only seen) to 5 (the epiglottis down folded and larynx cannot be seen directly) (10).~The scope will be manipulated to pass between the 2 vocal cords, and then advanced till the carina is seen to glide the suitable ETT into the trachea. Once the ETT is connected to the mechanical ventilator, chest auscultation and capnography waves will be used to confirm a successful intubation.~At any intubation attempt where SpO2 reaches 90%, the procedure will be suspended and mechanical ventilation via a facemask applied till SpO2 of 100% achieved.
Study NCT06776900 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lateral position
Description: An assistant will be asked to hold the tongue in protrusion using a gauze held by a Magill forceps (preventing it from falling backwards). The operator will introduce the bronchoscope orally allowing its advancement till it reaches the laryngeal inlet. The glottic view will be graded from 1 (larynx is only seen) to 5 (the epiglottis down folded and larynx cannot be seen directly) (10).~The scope will be manipulated to pass between the 2 vocal cords, and then advanced till the carina is seen to glide the suitable ETT into the trachea. Once the ETT is connected to the mechanical ventilator, chest auscultation and capnography waves will be used to confirm a successful intubation.~At any intubation attempt where SpO2 reaches 90%, the procedure will be suspended and mechanical ventilation via a facemask applied till SpO2 of 100% achieved.
Study NCT06771726 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RedScar App
Description: use of the RedScar© app on patients' smartphones. Patients will complete a brief health questionnaire and upload a wound photograph to the app, which will provide recommendations based on the risk of infection detected. Simultaneously, an in-person wound assessment will be conducted by the investigator to compare results.
Study NCT06256705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simultaneous 68Ga-DOTATOC PET-MRI
Description: on month before first cycle of 177Lu-DOTATATE, after second cycle and one year after first cycle
Study NCT06772415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci122 tablet 50mg
Description: Orally Once Daily
Study NCT06772415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GenSci122 tablet 250mg
Description: Orally Once Daily
Study NCT06778499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training for experimental group
Description: The experimental groups will undergo 3 interventions a week, with one session lasting 90 minutes. The experimental group will perform 15 minutes of dynamic stretching, 30 minutes of Latin dance-specific technique training, 30 minutes of plyometric training, and 15 minutes of relaxation stretching.
Study NCT06778499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional training for control group
Description: The control group will perform 15 minutes of dynamic stretching, 30 minutes of Latin dance-specific technique training, 30 minutes of general training, and 15 minutes of relaxation stretching.
Study NCT05337553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taldefgrobep alfa
Description: DB Phase: 35 mg/50 mg weekly subcutaneous injection
Study NCT05337553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: DB Phase: matching placebo 35 mg/50 mg weekly subcutaneous injection
Study NCT05337553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: taldefgrobep alfa
Description: Extension Phase: 35 mg/50 mg weekly subcutaneous injection
Study NCT05337553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: taldefgrobep alfa
Description: Extension Phase: 35 mg/50 mg weekly subcutaneous injection
Study NCT06612801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The REThink Game
Description: REThink is an online therapeutic game designed to improve the emotional well-being of young people, based on the principles of Rational Emotive Behavior Therapy (REBT). The game features a character named RETMAN, who leads players through seven levels, each dedicated to teaching a particular emotional regulation skill. Each level consists of three sub-levels that gradually become more challenging. REThink can be utilized as a standalone intervention, as a complement to self-help psychotherapeutic methods, or for focused skills training in emotional regulation. Each level trains a specific emoion-regulation skills such as emotion recognition, relaxation, cognitive change, problem solving, compassion and self-compassion.
Study NCT04825951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CS 2000
Description: treating growing Skeletal growing Class III patients
Study NCT05137314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLG0206
Description: PLG0206 is an engineered antibacterial peptide (EAP)
Study NCT05942820 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BWC0977
Description: SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
Study NCT04959864 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isitol®
Description: 1 sachet of Isitol® (2,1g) contains :~* 1000 mg of myo-inositol ;~* 300 mg of N-acetyl-cystein ;~* 48.5 mg of zinc citrate (equivalent zinc pure element : 15 mg) ;~* 35 mg of D-a-tocopherol (equivalent vitamin E pure element : 12 mg) ;~* 16 mg of vitamin B3 ;~* 1.8 mg of pyridoxin hydrochloride (equivalent vitamin B6 pure element : 1.4 mg) ;~* 1.4 mg of vitamin B2 ;~* 0.37 mg of (6S)-5-methyltetrahydrofolic acid, glucosamine salt (equivalent vitamin B9 pure element : 0.2 mg).~Sachets are packaged in box of 30.
Study NCT04959864 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 sachet of placebo (2,1g) contains :~* 1765.1 of maltodextrin ;~* 300 mg of magnesium carbonate ;~* 40 mg of citric acid ;~* 5.3 mg of beta-carotene ;~* 2.16 mg of silicon dioxide ;~* 1.44 mg of sucralose.~Sachets are packaged in box of 30.
Study NCT06412848 — intervention group
Intervention type: DRUG
Intervention: Avelumab
Description: This is an observational study, participants who received avelumab as first line maintenance therapy after a PBCT.
Study NCT05942820 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAD Cohorts: Two participants in each cohort will receive a matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.~Other Names:~• Compounded solution minus BWC0977
Study NCT05143632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClearSight
Description: The primary hypothesis is that continuous non-invasive monitoring using ClearSight reduces the incidence of intraoperative hypotensive events (defined by mean arterial pressure below a value of 65 mmHg for more than 1 minute) and the duration of the events themselves, leading to an improvement in patients' outcomes.
Study NCT06503068 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire in both digital and written forms in both Arabic and English versions.
Study NCT05138601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Collaborative Care Clinic
Description: Trained clinical pharmacists will monitor BP, prescribe and adjust medications and monitor for side effects of medications under the license of, and in communication with, the patient's physician.
Study NCT05672316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: Given IV
Study NCT05672316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05672316 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: Given IV
Study NCT05672316 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05672316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study NCT05575739 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of oxidative stress levels (Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins )
Description: Follicular fluid and serum were obtained within 1 hour of oocyte recovery. Considerable care was taken to pool follicular fluid uncontaminated with blood. The samples were processed by centrifuge and 1-mL aliquots stored ar -80ºC until assay. Malondialdehide, glutathione disulphate, total antioxidant capacity, superoxide dismutase and carbonylated proteins were measured from follicular fluid and plasma according to manufacturer's protocol. This assay has been described as highly sensitive. Data were expressed as millimoles per liter from the reference curve.
Study NCT05990790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.
Study NCT05990790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.
Study NCT05990790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: After induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
Study NCT05723757 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood sampling
Description: Draw a 8.5mL blood sample for detection of SNPs of genomic origin
Study NCT06126458 — intervention group
Intervention type: OTHER
Intervention: shooting performance
Description: collecting total points after 72 target shootings done
Study NCT04806438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: Patient will receive 5 ml of 10% lignocaine by air driven jet nebulizer for 20 min
Study NCT04806438 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: Patients will receive bilateral superior laryngeal nerve block and transtracheal instillation of 4 ml of 2% lignocaine, along with viscous xylocaine gargles twice
Study NCT05829798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNOLIS VA 80/160
Description: Single 4mL intra-articular injection of SYNOLIS VA 80/160
Study NCT05829798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNOLIS VA 40/80
Description: Single 2mL intra-articular injection of SYNOLIS VA 40/80
Study NCT06409234 — intervention group
Intervention type: OTHER
Intervention: Transthoracic Echocardiography Recieved
Description: Transthoracic Echocardiography Recieved
Study NCT05852665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided resection
Description: Ultrasound-guided resection of buccal squamous cell carcinomas
Study NCT05970705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: this anti-angiogenesis targeting drug is one of the standard third-line treatment options for patients with metastatic colorectal cancer
Study NCT05970705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: this anti-angiogenesis targeting drug is one of the standard third-line treatment options for patients with metastatic colorectal cancer
Study NCT05970705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/Tipiracil
Description: this chemotherapeutic drug is also one of the standard third-line treatment options for patients with metastatic colorectal cancer
Study NCT05922982 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: norepinephrine weaning protocol
Description: MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol
Study NCT05922982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: norepinephrine weaning protocol and guided by the HPI
Description: MAP-based (MAP > 65 mmHg) norepinephrine weaning protocol and guided by the HPI (HPI\<80) delivered by the Acumen IQ medical device.
Study NCT05597813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microneedling
Description: 15 patients will be subjected to microneedling alone. Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
Study NCT05597813 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microneedling with topical timolol 0.5%
Description: 15 patients will be subjected to microneedling with topical timolol 0.5%.Selected patients will receive one session with two weeks interval till complete clearance or up to 6 sessions.
Study NCT05035147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albumin-bound paclitaxel
Description: Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle
Study NCT05035147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel
Description: Experimental:Albumin-bound paclitaxel combined with gemcitabine was administered on the first and eighth day, a cycle of three weeks Active Comparator: Albumin-bound paclitaxel combined with gemcitabine was administered on the first, eighth, and fifteenth days, with a four-week cycle
Study NCT06196775 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK104+AK112
Description: Cadonilimab (AK104): 10mg/kg or 15mg/kg Q6W iv D8 (dose choosing depends on the outcome of the dose climb stage) AK112: 20mg/kg Q3W iv D1 Eligible patients will receive AK104 plus AK112 until disease progression or withdrawn ICF or death, whichever comes first.
Study NCT06331455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Two doses of durvalumab (1500 mg IV)
Study NCT06331455 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Non-ablative oligofractionated radiation (NORT)
Description: 12 Gy of Radiation in 3 fractions
Study NCT06441253 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Deep Friction massage
Description: The calf muscles received a firm, deep-circulation massage with fingertip pressure
Study NCT06441253 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Therapeutic exercises
Description: Four stretching exercises were performed for twenty minutes, five minutes for each technique, and eight to ten repetitions of each exercise (calf wall stretch, back knee straight, bilateral calf stretches, knees straight, ankle plantarflexion/dorsiflexion)
Study NCT05695729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLYOMETRIC EXERCISE PROGRAM
Description: This group will perform following exercises in first four weeks. Reverse overhead throw Rotational wall throws Overhead medicine ball Chest passes Resistance tubing 90-90 external rotation~Frequency~* Rest between Exercises-: 60-120 Seconds~* Rest between Set of Exercise-: 45-60 Seconds after four weeks rest between exercise and rest between set of exercise will be reduced:~* Rest between Exercises-: 45-60 Seconds~* Rest between Set of Exercise-: 20-30 Seconds~Tools used:~Medicine Ball, Resistance band
Study NCT05695729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CONVENTIONAL EXERCISE PROGRAM
Description: This group will perform following exercise through out the session with different frequencies after 4 weeks Bench presses Triceps kickbacks bicep curls Overhead presses Push-ups~Frequency:~Rest between Exercises-: 60-120 Seconds Rest between Set of Exercise-: 45-60 Seconds~After 4 weeks the frequency will be:~Rest between Exercises-: 45-60 Seconds Rest between Set of Exercise-: 20-30 Seconds
Study NCT06106880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Wintergreen Throat Spray and Aspirin Tablet
Description: The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Aspirin in a 325mg tablet
Study NCT06106880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin Throat Spray and Placebo Tablet
Description: The liquid spray contained 6mg dissolved acetyl salicylic acid per dose, menthol, lactoferrin, lysozyme, aloe, and glycerin.~Placebo Tablet: Looked like the treatment aspirin tablet but contained no drug and only inactive excipients.
Study NCT06106880 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wintergreen Throat Spray and Placebo Tablet
Description: The liquid spray contained wintergreen oil, menthol, lactoferrin, lysozyme, aloe, and glycerin.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients.
Study NCT06106880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Throat Spray and Placebo Tablet
Description: The placebo spray contained vehicle buffer, a sub-therapeutic dose of menthol, and a sweetener.~The placebo tablet looked like the treatment aspirin tablet but contained no drug and only inactive excipients.
Study NCT06306170 — intervention group
Intervention type: RADIATION
Intervention: Image Guided Radiotherapy
Description: Patients treated with IGRT, IMRT, SBRT for Gynecological cancer will be evaluated
Study NCT04915274 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: uses of an application
Description: Patients will be advised that they can still use their QuestOnco handset if they are hospitalized only for a treatment-related toxicity.
Study NCT04434326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14]CM082 suspension
Description: Before administration, the solid powder for administration was placed at room temperature. 40 ml drinking water was added into the drug container to prepare the suspension for the subjects to take. After that, 200 ml drinking water was used to repeatedly rinse the drug container for many times, and the subjects continued to take the lotion. Take care not to spill the liquid out of the bottle when shaking
Study NCT04854759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amantadine Hydrochloride
Description: 100 mg, capsule
Study NCT04854759 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg, capsule
Study NCT04927897 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: 3D endorectal ultrasound.
Study NCT04927897 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rectoscopy
Description: Rigid rectoscopy.
Study NCT04927897 — intervention group
Intervention type: OTHER
Intervention: Scan, e.g. CT (resection specimen)
Description: For some patients, images of the resection specimen (note: NOT of the patients) during the pathological process will be acquired.
Study NCT04850664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBOT + TAU
Description: The CBOT with proprietary odorant molecules is designed to stimulate olfactory neural activity over long periods of time. It is paired with OFC-dependent cognitive tasks.
Study NCT04850664 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham + TAU
Description: Sham CBOT device uses artificially scented compressed room air instead of olfactory stimulants and has control cognitive tasks.
Study NCT06169072 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Superparamagnetic Iron Oxide
Description: Superparamagnetic iron oxide (SPIO) consists of an iron oxide nanoparticle core and a hydrophilic coating to make it biocompatible and colloidal stable in a suspension. In this study injected intradermally in an ultra-low dose
Study NCT06169072 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Technetium99
Description: Technetium99 +/- blue dye is injected per routine as a comparator and as back up.
Study NCT04941053 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: laboratory test
Description: seroprevalnce
Study NCT05134987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0363-0845
Description: Participants will receive 0.5 nmol/kg NNC0363-0845 s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 3 nmol/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
Study NCT05134987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Description: Participants will receive 0.083 U/kg insulin detemir s.c. (subcutaneous - under the skin) every 4 hours up to 6 times daily (i.e. 0.5 U/kg/day) for 3 days The study will last for about 6 weeks up to a maximum of 14 weeks
Study NCT06314100 — intervention group
Intervention type: DEVICE
Intervention: Tobacco heating systems
Description: The study aims to explore the effect of tobacco heating system consumption on microbiome of the supragingival dental biofilm and the risk of developing caries lesions